Know Cancer

or
forgot password

Prevalence of Chronic Obstructive Pulmonary Disease in HIV-patient Population


N/A
18 Years
N/A
Open (Enrolling)
Both
Chronic Obstructive Pulmonary Disease

Thank you

Trial Information

Prevalence of Chronic Obstructive Pulmonary Disease in HIV-patient Population


The management of HIV is mainly represented by its commorbidities (cardio-vascular disease,
nephrologic, neurologic, osteo-articular disease, chronic hepatitis and cancer no linked to
immunodepression). COPD prevalence has never been studied in HIV population. In consequence,
there is no guideline about the screening, treatment or follow-up of COPD in HIV patients.
However this population seems particularly at risk to develop COPD because of high tobacco
consumption and accelerate ageing. Thus, we need an epidemiologic study to understand the
prevalence of COPD in HIV population in order to organize a specific screening and
follow-up. This is supported by an improvement of COPD if early managed. On top of that,
COPD screening will increase awareness of HIV patients on the problematic of tobacco
consumption.

Inclusion Criteria


Inclusion criteria:

- HIV seropositivity

- Age > 18 years

- Written aggreeing

- Affiliated or profit of a social coverage

Non inclusion criteria:

- Age < 18 years old

- Actual infectious pneumonia

- COPD exacerbation last 2 months *

- Recent (less than 1 month) myocardial infarction

- Thoracic or abdominal pain

- Enable to answer question secondary to mental deficienty**

- Physic or mental incapacity to realise COPD-6 or spirometery

- Urinary incontinency with effort

- Prisoner

- Refuse of consent or incapacity to give his consent

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Evaluation of Chronic obstructive pulmonary disease prevalence in a large population of HIV patients

Outcome Description:

An auto-questionnaire will be given to each patient included in the study (concern respiratory symptoms, tobacco consummation, illicit drug use, various respiratory exposition and lifestyle). Each patient will release a rapid evaluation of respiratory capacity with COPD-6. Patients screened with abnormal respiratory symptoms on auto-questionnaire, or with a risk of COPD ranked from high to moderate by COPD-6 test will benefit of a conventional spirometry.

Outcome Time Frame:

one time each patient (one hour)

Safety Issue:

No

Principal Investigator

Karine RISSO, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

CHU Nice

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

11-PP-09

NCT ID:

NCT01639274

Start Date:

January 2012

Completion Date:

November 2013

Related Keywords:

  • Chronic Obstructive Pulmonary Disease
  • Acquired Immunodeficiency Syndrome
  • HIV Infections
  • Lung Diseases
  • Respiration Disorders
  • Pulmonary Disease, Chronic Obstructive
  • Lung Diseases, Obstructive

Name

Location